Multi-center randomized study of prophylactic effect of Landiorol for prevention of atrial fibrillation after cardiac surgery.

Multi-center randomized study of prophylactic effect of Landiorol for prevention of atrial fibrillation after cardiac surgery. - Prophylactic effect of Landiorol for prevention of atrial fibrillation after cardiac surgery.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004433

Enrollment

200

Registered

2010-12-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation after cardiac surgery

Interventions

Continuous infusion of Landiorol at a rate of 2 microgram/kg/min from POD1 to POD3 Untreated

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All adult patients undergoing cardiac surgery

Exclusion criteria

Exclusion criteria: Cardiogenic shock, chronic atrial fibrillation, bronchial asthma, pulmonary hypertension, untreated pheochromocytoma, severe bradycardia including A-V block more than II degree, severe allergy to Landiorol, a judgement of attending physician that patient participation would be inappropriate

Design outcomes

Primary

Measure	Time frame
Incidence of atrial fibrillation after cardiac surgery	—

Secondary

Measure	Time frame
Degree and frequency of adverse events(death, stroke, MI, LOS, severe bradycardia, severe hypotension or decrease of CI)	—

Countries

Japan

Contacts

Public ContactKentaro Takaji

Kumamoto University Department of Cardiovascular Surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026